<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01346150</url>
  </required_header>
  <id_info>
    <org_study_id>DAIT RDCRN PIDTC-6902</org_study_id>
    <nct_id>NCT01346150</nct_id>
  </id_info>
  <brief_title>Patients Treated for SCID (1968-Present)</brief_title>
  <official_title>A Retrospective and Cross-Sectional Analysis of Patients Treated for SCID Since January 1,1968 (RDCRN PIDTC-6902)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rare Diseases Clinical Research Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Primary Immune Deficiency Treatment Consortium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      People with Primary Immune Deficiency (PID) may develop severe, life-threatening infections
      as a result of inherited defects in the genes that normally instruct blood-forming cells to
      develop and to fight infections. PID diseases include Severe Combined Immune Deficiency
      (SCID), leaky SCID, Omenn syndrome (OS), and Reticular Dysgenesis (RD). PIDs may be treated
      by transplantation of bone marrow stem cells from a healthy person or, in some cases, by
      enzyme replacement or by gene therapy. Patients with SCID were among the first to receive
      bone marrow stem cell (also called hematopoietic cells) transplantation (HCT) more than 40
      years ago, and HCT is the standard treatment today for this group of diseases. Since PID
      diseases are rare, there are not enough patients at any single center to determine the full
      range of causes, natural history, or best methods of treatment. For this research study many
      PID centers across North America have organized into the Primary Immune Deficiency Treatment
      Consortium (PIDTC) to pool their experience and study PIDs together. Researchers will collect
      information on your general health, psychological and developmental health, and the current
      status of your immune system to help better define future approaches to PID treatments.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Retrospective Study - Part 1</measure>
    <time_frame>1, 5, 10, 20, &gt;20 years</time_frame>
    <description>Overall survival</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cross-Sectional Study - Part 2</measure>
    <time_frame>2 to &gt; 20 years</time_frame>
    <description>Full immune reconstitution</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Retrospective Study Part 1</measure>
    <time_frame>1 year to &gt; 20 years</time_frame>
    <description>Immune reconstitution and clinical outcomes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retrospective Study - Part 1</measure>
    <time_frame>3 months to &gt;20 years</time_frame>
    <description>Engraftment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cross-Sectional Study - Part 2</measure>
    <time_frame>2 to &gt;20 years</time_frame>
    <description>Current state of lineage-specific chimerism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cross-Sectional Study - Part 2</measure>
    <time_frame>2 to &gt;20 years</time_frame>
    <description>Current status of health</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">1146</enrollment>
  <condition>SCID</condition>
  <condition>ADA-SCID</condition>
  <condition>XSCID</condition>
  <condition>Leaky SCID</condition>
  <condition>Omenn Syndrome</condition>
  <condition>Reticular Dysgenesis</condition>
  <arm_group>
    <arm_group_label>Stratum A</arm_group_label>
    <description>SCID, ADA-SCID, and XSCID who received a transplant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stratum B</arm_group_label>
    <description>Leaky SCID, Omenn Syndrome, and Reticular Dysgenesis who received a transplant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stratum C</arm_group_label>
    <description>SCID who received PEG ADA or gene therapy</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Biospecimens may include blood, other tissues (e.g., buccal swab or brushing), and/or bone
      marrow.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals with diagnosis of SCID or SCID variants treated at Participating Consortium
        Centers from 1968-Present
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Strata A, B, and C (Part 1 - Retrospective Study)-

          -  Individuals with Severe Combined Immune Deficiency (SCID) diagnosis who:

             --were treated at a location participating in this consortium from 1968 until present,
             and

             --are not enrolled in RDCRN PIDTC-6901 (ClinicalTrials.gov ID: NCT01186913).

          -  Subjects who received HCT/GT/ERT prior to the present date are eligible for the
             retrospective study. The enrollment criteria for subjects who died prior to definitive
             therapy are the same as for Strata A, B and C.

        Stratum A, Typical SCID:

          -  Individuals who meet the following inclusion criteria and who received HCT are
             eligible for enrollment into Stratum A (Classic SCID) of the study:

               -  Absence or very low number of T cells (CD3 T cells &lt; 300/microliter), and no or
                  very low T cell function (&lt; 10% of lower limit of normal) as measured by response
                  to phytohemagglutinin (PHA) or cells of maternal origin present.

               -  If maternal cells are present but the patient does not meet criteria for very low
                  T cell function as defined, the assigned reviewers for the potential subject, and
                  if necessary, the full PID‐SCID RP will review the laboratory report to determine
                  if criteria of maternal engraftment are met for Protocol 6902.

               -  Laboratory report of testing for maternal engraftment is required, for evaluation
                  by the PID‐SCID RP.

        Stratum B, Leaky SCID, Omenn Syndrome, Reticular Dysgenesis:

        Individuals who meet the following criteria are eligible for enrollment into Stratum B of
        the study:

        Leaky SCID-

          -  Maternal lymphocytes tested for and not detected and,

          -  Either one or both of the following (a,b):

             a) &lt; 50% of lower limit of normal T cell function (as measured by response to PHA OR &lt;
             50% of lower limit of normal T cell function as measured by response to CD3/CD28
             antibody, b) Absent or &lt; 30% lower limit of normal proliferative responses to candida
             and tetanus toxoid antigens postvaccination or exposure,

          -  AND at least one of the following (a through e):

               1. Reduced number of CD3 T cells,

               2. &gt; 80% of CD3+ or CD4 T cells are CD45RO+,

          -  AND/OR &gt;80% of CD3+ or CD4+ T cells are,CD62L negative,

          -  AND/OR &gt;50% of CD3+ or CD4+ T cells express HLA‐DR (at &lt; 4 years of age),

          -  AND/OR are oligoclonal T cells. c) Hypomorphic mutation in IL2RG in a male, or
             homozygous hypomorphic mutation or compound heterozygosity with at least one
             hypomorphic mutation in an autosomal SCID‐causing gene.

             d) Low TRECs and/or the percentage of CD4+/45RA+/CD31+ or CD4+/45RA+/CD62L+ cells is
             below the lower limit of normal.

             e) Functional testing in vitro supporting impaired, but not absent, activity of the
             mutant protein,

               -  AND does not meet criteria for Omenn Syndrome,

               -  AND does not have known selective loss of lymphocytes, Ataxia‐ Telangiectasia, or
                  congenital heart defect associated with lymphopenia, unless a SCID genotype is
                  also present.

        Omenn Syndrome (OS):

          -  Generalized skin rash,

          -  Maternal engraftment tested for and not detected,

          -  Absent or low (up to 30% of normal) T cell proliferation to antigens to which the
             patient has been exposed.

          -  If the proliferation to antigen was not performed, but at least 4 of the following 10
             supportive criteria, at least one of which must be among those marked with an asterisk
             (*) are present, the patient is eligible: hepatomegaly; splenomegaly; lymphadenopathy;
             elevated IgE; elevated absolute eosinophil count; *oligoclonal T cells measured by
             CDR3 length or flow cytometry &gt;80% of CD4+ T cells are CD45RO+ ;*proliferation to PHA
             is reduced &lt;50% of lower limit of normal or SI &lt;30; *proliferative response in mixed
             leukocyte reaction is reduced to increment cpm &lt; 20% or SI &lt;20; hypomorphic mutation
             to SCID causing gene; low TRECs and/or percentage of CD 4+/ RA+/CD31+; or
             CD4+/RA+/CD62L+ cells below the lower limit of normal.

        Reticular Dysgenesis (RD):

          -  Absence or very low number of T cells (CD3 T cells &lt;300/microliter),

          -  No or very low (&lt;10% of lower limit of normal) T cell function (as measured by
             response to phytohemagglutinin (PHA),

          -  Severe congenital neutropenia (absolute neutrophil count &lt;200/microliter),

          -  AND at least one of the following:

               -  Sensorineural deafness and/or absence of granulopoiesis at bone marrow
                  examination and/or a deleterious AK2 mutation,

               -  absence of granulopoiesis on bone marrow examination; a pathogenic mutation in
                  the adenylate kinase 2 (AK2) gene identified.

        Stratum C, SCID with Non-HCT Treatments:

        -Individuals who meet the following criteria and were treated with PEG-ADA or gene therapy
        with autologous modified cells are eligible for enrollment into Stratum C (SCID with
        non-HCT treatments) of the study-

        - Any SCID patient previously treated with a thymus transplant (includes intention to treat
        with HCT, as well as PEG‐ADA ERT or gene therapy).

        Strata A, B, and C (Part 2 - Cross-Sectional Study):

        Patient inclusion criteria for the cross sectional study: Eligibility for Strata A, B and C
        are the same as for the retrospective study except that all the patients in the
        cross-sectional study are currently surviving and are at least 2 years post the most recent
        class of therapy.

        Exclusion Criteria:

        Parts 1 and 2 - Retrospective and Cross-Sectional Studies -

          -  Lack of appropriate testing to rule out HIV infection after 1997 (p24 antigen or more
             sensitive) or other cause of secondary immunodeficiency,

          -  Presence of DiGeorge syndrome,

          -  Most patients with other PIDs such as nucleoside phosphorylase deficiency, ZAP70
             deficiency, CD40 ligand deficiency, NEMO deficiency, XLP, cartilage hair hypoplasia or
             ataxia telangiectasia will not meet the inclusion criteria for Stratum A, B, or C
             above; however, a patient with one of the above may meet the inclusion criteria for
             Stratum B and if so will be included-

               -  MHC Class I and MHC Class II antigen deficiency are excluded,

               -  Metabolic conditions that imitate SCID or related disorders such as folate
                  transporter deficiency, severe zinc deficiency, transcobalamin deficiency.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Morton J Cowan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCSF Children's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elie Haddad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Justine's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fredrick Goldman, MD</last_name>
      <phone>205-939-5855</phone>
      <email>fgoldman@peds.uab.edu</email>
    </contact>
    <investigator>
      <last_name>Fredrick Goldman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renna Killen, RN</last_name>
      <phone>323-361-2217</phone>
      <email>rkillen@chla.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Neena Kapoor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1752</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theodore Moore, MD</last_name>
      <phone>310-825-6708</phone>
      <email>TBMoore@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Theodore Moore, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco Children's Hospital</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-1278</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Dunn</last_name>
      <phone>415-476-4860</phone>
      <email>DunnE@peds.ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Morton Cowan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katja Weinacht, MD</last_name>
      <phone>650-725-6520</phone>
      <email>kgw1@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Katja Weinacht, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Denver</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Craddock, MD</last_name>
      <phone>720-777-3328</phone>
      <email>John.Craddock@childrenscolorado.org</email>
    </contact>
    <investigator>
      <last_name>John Craddock, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010-2970</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Blachy Saldaña, MD</last_name>
      <phone>202-476-4561</phone>
      <email>Bjdavilas1@childrensnational.org</email>
    </contact>
    <investigator>
      <last_name>Blachy Saldaña, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>All Children's Hospital, St. Petersburg FL</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin Oshrine, MD</last_name>
      <phone>727-767-4176</phone>
      <email>Boshrin1@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Benjamin Oshrine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta/Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Stenger, MD</last_name>
      <phone>404-785-1272</phone>
      <email>Elizabeth.Stenger@choa.org</email>
    </contact>
    <investigator>
      <last_name>Elizabeth Stenger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Morris Kletzel, MD</last_name>
      <phone>773-880-4598</phone>
      <email>MKletzel16@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Morris Kletzel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital/Louisiana State University Health Sciences Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lolie Yu, MD</last_name>
      <phone>504-896-9740</phone>
      <email>lyu@lsuhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Lolie Yu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NIH Clinical Center Genetic Immunotherapy Section</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harry Malech, MD</last_name>
      <phone>301-480-6916</phone>
      <email>hmalech@mail.nih.gov</email>
    </contact>
    <investigator>
      <last_name>Harry Malech, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sung-Yun Pai, MD</last_name>
      <phone>617-919-2508</phone>
      <email>sung-yun.pai@childrens.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Sung-Yun Pai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Vander Lugt, MD</last_name>
      <phone>737-936-9814</phone>
      <email>marvande@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Mark Vander Lugt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angie Smith, MD</last_name>
      <phone>612-626-2778</phone>
      <email>smith719@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Angie Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardinal Glennon Children's Medical Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy Sanders, RN</last_name>
      <phone>314-268-2700</phone>
      <phone_ext>3513</phone_ext>
      <email>Wendy_Sanders@ssmhc.com</email>
    </contact>
    <investigator>
      <last_name>Alan Knutsen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University St Louis Children's Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shalini Shenoy, MD</last_name>
      <phone>314-454-6018</phone>
      <email>shenoy@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Shalini Shenoy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alfred Gillio, MD</last_name>
      <phone>201-996-5645</phone>
      <email>AGillio@HackensackUMC.org</email>
    </contact>
    <investigator>
      <last_name>Alfred Gillio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard J O'Reilly, MD</last_name>
      <phone>212-639-5957</phone>
      <email>oreillyr@mskc.org</email>
    </contact>
    <investigator>
      <last_name>Richard J O'Reilly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Buckley, MD</last_name>
      <phone>919-684-2922</phone>
      <email>buck1003@mc.duke.edu</email>
    </contact>
    <investigator>
      <last_name>Rebecca Buckley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharat Chandra, MD</last_name>
      <phone>513-636-5917</phone>
      <email>Sharat.Chandra@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>Sharat Chandra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evan Shereck, MD</last_name>
      <phone>503-494-0829</phone>
      <email>Shereck@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Evan Shereck, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen Sullivan, MD, PhD</last_name>
      <phone>215-590-1697</phone>
      <email>sullivak@mail.med.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Kathleen Sullivan, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ewelina Mamcarz, MD</last_name>
      <phone>901-595-8343</phone>
      <email>ewelina.mamcarz@stjude.org</email>
    </contact>
    <investigator>
      <last_name>Ewelina Mamcarz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center/Children's of Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victor Aquino, MD</last_name>
      <phone>214-648-8800</phone>
      <email>victor.aquino@utsouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Victor Aquino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-2399</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chivon McMullen-Jackson, RN, BSN</last_name>
      <phone>832-824-1339</phone>
      <email>cdmcmull@texaschildrens.org</email>
    </contact>
    <investigator>
      <last_name>William Shearer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Methodist Children's Hospital of South Texas/Texas Transplant Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Troy Quigg, MD</last_name>
      <phone>210-575-7348</phone>
      <email>Troy.Quigg@MHShealth.com</email>
    </contact>
    <investigator>
      <last_name>Troy Quigg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Primary Children's Medical Center/University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Shyr, MD</last_name>
      <phone>801-662-4736</phone>
      <email>David.Shyr@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>David Shyr, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington &amp; Seattle Children's Hospital/ Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauri M. Burroughs, MD</last_name>
      <phone>206-667-2396</phone>
      <email>lburroug@fhcrc.org</email>
    </contact>
    <investigator>
      <last_name>Lauri Burroughs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin/ American Family Children's Hospital</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705-2275</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth DeSantes, MD</last_name>
      <phone>608-263-8563</phone>
      <email>kbdesantes@pediatrics.wisc.edu</email>
    </contact>
    <investigator>
      <last_name>Kenneth DeSantes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226-4874</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Thakar, MD</last_name>
      <phone>414-266-6840</phone>
      <email>mthakar@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>Monica Thakar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alberta Children's Hospital</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3B 6A8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicola Wright, MD</last_name>
      <phone>403-955-3035</phone>
      <email>Nicola.Wright@albertahealthservices.ca</email>
    </contact>
    <investigator>
      <last_name>Nicola Wright, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>British Columbia Children's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 3V4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Davis, MD</last_name>
      <phone>(604) 875-3577</phone>
      <email>jdavis@cw.bc.ca</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Davis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Care Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marlis Schroeder, MD</last_name>
      <phone>(204) 787-4372</phone>
      <email>marlis.schroeder@cancercare.mb.ca</email>
    </contact>
    <investigator>
      <last_name>Marlis Schroeder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1XB</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eyal Grunebaum, MD</last_name>
      <phone>416-813-7654</phone>
      <email>Eyal.Grunebaum@sickkids.ca</email>
    </contact>
    <investigator>
      <last_name>Eyal Grunebaum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU St. Justine</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elie Haddad, MD</last_name>
      <phone>(514) 345-4931</phone>
      <phone_ext>6217</phone_ext>
      <email>elie.haddad@umontreal.ca</email>
    </contact>
    <investigator>
      <last_name>Elie Haddad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.niaid.nih.gov</url>
    <description>The National Institute of Allergy and Infectious Diseases (NIAID)</description>
  </link>
  <link>
    <url>http://rarediseasesnetwork.epi.usf.edu/index.htm</url>
    <description>The Rare Diseases Clinical Research Network (RDCRN)</description>
  </link>
  <link>
    <url>http://rarediseasesnetwork.epi.usf.edu/PIDTC/</url>
    <description>Primary Immune Deficiency Treatment Consortium (PIDTC)</description>
  </link>
  <reference>
    <citation>Griffith LM, Cowan MJ, Kohn DB, Notarangelo LD, Puck JM, Schultz KR, Buckley RH, Eapen M, Kamani NR, O'Reilly RJ, Parkman R, Roifman CM, Sullivan KE, Filipovich AH, Fleisher TA, Shearer WT. Allogeneic hematopoietic cell transplantation for primary immune deficiency diseases: current status and critical needs. J Allergy Clin Immunol. 2008 Dec;122(6):1087-96. doi: 10.1016/j.jaci.2008.09.045. Epub 2008 Nov 6.</citation>
    <PMID>18992926</PMID>
  </reference>
  <results_reference>
    <citation>Pai SY, Logan BR, Griffith LM, Buckley RH, Parrott RE, Dvorak CC, Kapoor N, Hanson IC, Filipovich AH, Jyonouchi S, Sullivan KE, Small TN, Burroughs L, Skoda-Smith S, Haight AE, Grizzle A, Pulsipher MA, Chan KW, Fuleihan RL, Haddad E, Loechelt B, Aquino VM, Gillio A, Davis J, Knutsen A, Smith AR, Moore TB, Schroeder ML, Goldman FD, Connelly JA, Porteus MH, Xiang Q, Shearer WT, Fleisher TA, Kohn DB, Puck JM, Notarangelo LD, Cowan MJ, O'Reilly RJ. Transplantation outcomes for severe combined immunodeficiency, 2000-2009. N Engl J Med. 2014 Jul 31;371(5):434-46. doi: 10.1056/NEJMoa1401177.</citation>
    <PMID>25075835</PMID>
  </results_reference>
  <results_reference>
    <citation>Shearer WT, Dunn E, Notarangelo LD, Dvorak CC, Puck JM, Logan BR, Griffith LM, Kohn DB, O'Reilly RJ, Fleisher TA, Pai SY, Martinez CA, Buckley RH, Cowan MJ. Establishing diagnostic criteria for severe combined immunodeficiency disease (SCID), leaky SCID, and Omenn syndrome: the Primary Immune Deficiency Treatment Consortium experience. J Allergy Clin Immunol. 2014 Apr;133(4):1092-8. doi: 10.1016/j.jaci.2013.09.044. Epub 2013 Nov 28.</citation>
    <PMID>24290292</PMID>
  </results_reference>
  <results_reference>
    <citation>Haddad E, Allakhverdi Z, Griffith LM, Cowan MJ, Notarangelo LD. Survey on retransplantation criteria for patients with severe combined immunodeficiency. J Allergy Clin Immunol. 2014 Feb;133(2):597-9. doi: 10.1016/j.jaci.2013.10.022. Epub 2013 Dec 10.</citation>
    <PMID>24331379</PMID>
  </results_reference>
  <results_reference>
    <citation>Griffith LM, Cowan MJ, Notarangelo LD, Kohn DB, Puck JM, Shearer WT, Burroughs LM, Torgerson TR, Decaluwe H, Haddad E; workshop participants. Primary Immune Deficiency Treatment Consortium (PIDTC) update. J Allergy Clin Immunol. 2016 Aug;138(2):375-85. doi: 10.1016/j.jaci.2016.01.051. Epub 2016 Apr 22. Review.</citation>
    <PMID>27262745</PMID>
  </results_reference>
  <results_reference>
    <citation>Griffith LM, Cowan MJ, Notarangelo LD, Kohn DB, Puck JM, Pai SY, Ballard B, Bauer SC, Bleesing JJ, Boyle M, Brower A, Buckley RH, van der Burg M, Burroughs LM, Candotti F, Cant AJ, Chatila T, Cunningham-Rundles C, Dinauer MC, Dvorak CC, Filipovich AH, Fleisher TA, Bobby Gaspar H, Gungor T, Haddad E, Hovermale E, Huang F, Hurley A, Hurley M, Iyengar S, Kang EM, Logan BR, Long-Boyle JR, Malech HL, McGhee SA, Modell F, Modell V, Ochs HD, O'Reilly RJ, Parkman R, Rawlings DJ, Routes JM, Shearer WT, Small TN, Smith H, Sullivan KE, Szabolcs P, Thrasher A, Torgerson TR, Veys P, Weinberg K, Zuniga-Pflucker JC; workshop participants. Primary Immune Deficiency Treatment Consortium (PIDTC) report. J Allergy Clin Immunol. 2014 Feb;133(2):335-47. doi: 10.1016/j.jaci.2013.07.052. Epub 2013 Oct 15.</citation>
    <PMID>24139498</PMID>
  </results_reference>
  <results_reference>
    <citation>Dvorak CC, Cowan MJ, Logan BR, Notarangelo LD, Griffith LM, Puck JM, Kohn DB, Shearer WT, O'Reilly RJ, Fleisher TA, Pai SY, Hanson IC, Pulsipher MA, Fuleihan R, Filipovich A, Goldman F, Kapoor N, Small T, Smith A, Chan KW, Cuvelier G, Heimall J, Knutsen A, Loechelt B, Moore T, Buckley RH. The natural history of children with severe combined immunodeficiency: baseline features of the first fifty patients of the primary immune deficiency treatment consortium prospective study 6901. J Clin Immunol. 2013 Oct;33(7):1156-64. doi: 10.1007/s10875-013-9917-y. Epub 2013 Jul 2.</citation>
    <PMID>23818196</PMID>
  </results_reference>
  <results_reference>
    <citation>Griffith LM, Cowan MJ, Notarangelo LD, Puck JM, Buckley RH, Candotti F, Conley ME, Fleisher TA, Gaspar HB, Kohn DB, Ochs HD, O'Reilly RJ, Rizzo JD, Roifman CM, Small TN, Shearer WT; Workshop Participants. Improving cellular therapy for primary immune deficiency diseases: recognition, diagnosis, and management. J Allergy Clin Immunol. 2009 Dec;124(6):1152-60.e12. doi: 10.1016/j.jaci.2009.10.022.</citation>
    <PMID>20004776</PMID>
  </results_reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2011</study_first_submitted>
  <study_first_submitted_qc>April 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2011</study_first_posted>
  <last_update_submitted>November 7, 2017</last_update_submitted>
  <last_update_submitted_qc>November 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Severe Combined Immunodeficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

